Dao-Zhou Liu
Overview
Explore the profile of Dao-Zhou Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
262
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang Q, Liu D, Liu M, Ji Q, Mei Q, Cheng Y, et al.
J Pharm Sci
. 2024 Jan;
113(4):1121-1122.
PMID: 38290614
No abstract available.
2.
Yang Q, Liu D, Liu M, Ji Q, Mei Q, Cheng Y, et al.
J Pharm Sci
. 2020 Nov;
110(2):876-887.
PMID: 33166581
Prostate cancer is the most common malignant tumor with bone metastasis, and there is still no ideal treatment for bone metastasis of prostate cancer. In this study, a pH and...
3.
Bai S, Cheng Y, Liu D, Ji Q, Liu M, Zhang B, et al.
Nanomedicine (Lond)
. 2020 Mar;
15(9):833-849.
PMID: 32163008
To prepare pH-sensitive nanoparticle composed of alendronate (ALN) and poly(amidoamine) (PAMAM) to treat bone metastases of lung cancer. The solvent evaporation method was used to prepare docetaxel (DTX)-loaded ALN-PAMAM nanoparticles...
4.
Bai S, Liu D, Cheng Y, Cui H, Liu M, Cui M, et al.
Nanomedicine
. 2019 Jul;
21:102054.
PMID: 31310809
Bone is one of the prone metastatic sites of lung cancer. Osteoclast plays an important role in bone resorption and the growth of bone metastases of lung cancer. In order...
5.
Li H, Ye W, Huan M, Cheng Y, Liu D, Cui H, et al.
Nanomedicine (Lond)
. 2019 Mar;
14(8):1011-1032.
PMID: 30925116
Aim: The objective of this study was to deliver a ring-closed form of 10-hydroxycamptothecin (HCPT) to the mitochondria and nucleus to treat colorectal cancer. Materials & Methods: HCPT-loaded nanoparticle HCPT@PLGA-PEG-triphenylphosphonium/PLGA-hyd-PEG-folic...
6.
Zhang C, Cheng Y, Liu D, Liu M, Cui H, Zhang B, et al.
J Nanobiotechnology
. 2019 Jan;
17(1):18.
PMID: 30683110
Background: Cyclosporin A (CsA) is a promising therapeutic drug for myocardial ischemia reperfusion injury (MI/RI) because of its definite inhibition to the opening of mitochondrial permeability transition pore (mPTP). However,...
7.
Cheng Y, Liu D, Zhang C, Cui H, Liu M, Zhang B, et al.
Nanomedicine
. 2019 Jan;
16:236-249.
PMID: 30639669
Efficient delivery of antioxidant drugs into mitochondria of ischemic cardiomyocytes where reactive oxygen species largely induced is a major challenge for precise treatment of myocardial ischemia-reperfusion injury. Herein, we report...
8.
Song Y, Liu D, Cheng Y, Teng Z, Cui H, Liu M, et al.
Mol Pharm
. 2018 Feb;
15(3):1296-1308.
PMID: 29432025
The experiment aims to increase antitumor activity while decreasing the systemic toxicity of doxorubicin (DOX). Charge reversible and mitochondria/nucleus dual target lipid hybrid nanoparticles (LNPs) was prepared. The in vitro...
9.
Liu D, Cheng Y, Cai R, Wang Bd W, Cui H, Liu M, et al.
Nanomedicine
. 2018 Jan;
14(3):991-1003.
PMID: 29339188
In order to enhance the penetration of small interference RNA against the polo-like kinase I (siPLK1) across BBB to treat glioblastoma (GBM), transferrin (Tf) modified magnetic nanoparticle (Tf-PEG-PLL/MNP@siPLK1) was prepared....
10.
Ye W, Zhao Y, Cheng Y, Liu D, Cui H, Liu M, et al.
Artif Cells Nanomed Biotechnol
. 2018 Jan;
46(sup1):380-391.
PMID: 29336169
In order to inhibit the growth of lung cancer bone metastasis and reduce the bone resorption at bone metastasis sites, a bone metastasis target micelle DOX@DBMs-ALN was prepared. The size...